盐疗联合噻托溴胺治疗稳定期重度慢性阻塞性肺疾病的临床刍议  

Clinical Discussion on the Treatment of Stable Chronic Obstructive Pulmonary Disease with the Combination of Salt Therapy and the Treatment of the Patients with Chronic Obstructive Pulmonary Disease

作　　者：林友飞 吴迪 陈晓红 陈力舟 

机构地区：[1]福建省福州医院肺科,福建福州350008

出　　处：《中外医疗》2016年第30期111-114,共4页China & Foreign Medical Treatment

摘　　要：目的探讨噻托溴胺联合盐疗治疗稳定期重度慢性阻塞性肺疾病(COPD)缓解期患者的疗效。方法方便选取该院2013年1月—2014年1月期间收治的72例COPD患者作为研究对象,根据治疗方法的不同随机分为4组:对照组19例;噻托溴胺17例;噻托溴胺+盐疗18例;盐疗组18例治疗。治疗后12个月分别观察肺功能及因COPD住院次数。结果四组患者治疗前肺功能指标对比差异无统计学意义(P>0.05),治疗后对照组患者肺功能指标差异无统计学意义(P>0.05),其他各组患者的FEV_1、FEV_1/FVC以及FEV_1等肺功能指标均明显增加(P<0.05),其中噻托溴胺+盐疗组的FEV_1、FEV_1/FVC以及FEV_1增加值分别为(0.17±0.05)L、(6.66±1.57)%以及(5.01±1.11)%,明显高于噻托溴胺组[(0.10±0.03)L、(6.31±1.49)%以及(3.64±0.62)%]和盐疗组[(0.04±0.03)L、(2.28±2.33)%以及(1.28±0.57)%],对比差异有统计学意义(P<0.05)。噻托溴胺+盐疗组的患者治疗后1年内因COPD发病次数明显低于其他3组,对比差异有统计学意义(P<0.05)。结论重度COPD缓解期患者使用盐疗联合噻托溴胺治疗可减少因COPD导致住院的次数且更好改善肺功能。Objective To observe the effects of tiotropium bromide and halotherapy in patients with severe stable chronic obstructive pulmonary disease（COPD）. Methods Convenient selected in our hospital from January 2013 to January 2004 were 72 cases of COPD patients as the research object, according to the different treatment methods were randomly divided into into 4 groups： control group（19 cases）; tiotropium in 17 cases; tiotropium bromide ＋ salt treatment in 18 cases; salt treatment group 18 cases were treated. After treatment for 12 months were observed lung function and COPD hospitalization.Results Four groups of patients before lung function index contrast little（P〉0.05） treatment, after treatment, the control group the patients＇ pulmonary function index had no significant change（P〉0.05）, the other groups of patients with FEV1,FEV1/ FVC and FEV1 lung function index such as increased significantly（P〈0.05）, which tiotropium bromide ＋ salt therapy group of FEV1, FEV1/ FVC and FEV1 increase in value respectively（0.17± 0.05）L, 6.66 ＋ 1.57）% and（5.01±1.11）% was significantly higher than that of thiophene supporting bromide Group [（0.10±0.03）L,（6.31 ＋ 1.49）% and（3.64±0.62）%] and salt treatment group [（0.04±0.03）L,（2.28±2.33）% and（1.28±0.57）%], difference significantly With（P〈0.05）. Tiotropium bromide ＋ salt treatment group of the patients after 1 year internal COPD incidence number was significantly lower than that of the other three groups, significant differences（P〈0.05）. Conclusion For the patients with severe COPD remission patients using salt therapy combined tiotropium bromide treatment can be reduced due to COPD lead to hospitalization frequency and improve lung function.

关 键 词：盐疗 噻托溴胺 稳定期 重度慢性阻塞性肺疾病 

分 类 号：R5[医药卫生—内科学]